Skip Navigation Links
SEARCH  



 
Bookmark and Share
Connect Biopharma to Present Additional Positive Results from the Phase 1b Study of CBP-201 for Patients with Moderate-to-Severe Atopic Dermatitis (AD) at EADV Virtual Meeting
SAN DIEGO and TAICANG, SUZHOU, China, Oct. 22, 2020 /PRNewswire/ -- Connect Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immune modulators for t...

Full "IntellAsia: Resources" article




Disclaimer | Terms Of Use And Privacy Statement


© Metals News. All rights reserved.